A disease hidden in plain sight: Interview with Walter Koroshetz and Zaher Nahle

I just need to say that Llewellyn King irritates me at times. Obviously a very eloquent man providing valuable advocacy for us, but also prone to interrupting and talking over people that he interviews. Thinking about it as I type, this always irritated me immensely when I was still working, as it frequently meant that I lost track of what I was saying and had to mentally 'reboot', so I guess I'm just projecting that on to him, but knowing that still doesn't stop it winding me up.

And despite that bugbear of mine, I think it's a great interview, and I also agree with @Joel , I also rate Dr Nahle.
 
Last edited by a moderator:


Llewellyn King:

Dear Friends,

I'm delighted to let you know that a new video, Episode #94, is available on ME/CFS Alert on YouTube. The episode features my interview with Dr. Walter Koroshetz of the National Institutes of Health and Dr. Zaher Nahle, scientific director of the Solve ME/CFS Initiative.

The ME/CFS Alert episode was recorded right after I filmed a half-hour episode of my television program, "White House Chronicle." The TV episode, which aired last week, was produced with active support from the Solve ME/CFS Initiative and its president, Carol Head.

The material in Episode #94 doesn't duplicate the material in the longer TV episode, which can be viewed on the "White House Chronicle" website whchronicle.com.

As always, I ask that you forward the ME/CFS Alert episode to friends and interested persons.

Good wishes,

Llewellyn

Executive Producer and Host,
"White House Chronicle" on PBS;
Contributor, HuffPost;
Columnist, InsideSources Syndicate;
Commentator, SiriusXM Radio
 
November 2017 Research 1st – Dr. Nahle Letter
November 15, 2017

Dear Friends,

The recent conversation with the National Institute of Neurological Disorders and Stroke (NINDS) Director, Dr. Walter Koroshetz, on an episode of the White House Chronicle, was a timely assessment of current ME/CFS affairs. This wide-ranging science and policy conversation is particularly meaningful at this juncture.

  • First, it offers a comprehensive summary of how the NIH is currently approaching ME/CFS – a clear departure from the past.
  • Second, it emphasizes the biological complexity of this disease while acknowledging the years of deficient investment at all levels in the ME/CFS space.
  • Third, it outlines a process for building capacity and infrastructure, with the recently announced consortium of centers solely dedicated to ME/CFS as a starting point.
http://solvecfs.org/november-2017-research-1st-dr-nahle-letter-2/
 
Back
Top Bottom